Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection

Liver International

Volumn 37, Issue 1, 2017, Pages 35-44

  Zou, Xia ^a,b,c   Zhu, Ming Yu ^a   Yu, De Min ^a   Li, Wei ^b   Zhang, Dong Hua ^a   Lu, Fei Jie ^b   Gong, Qi Ming ^a   Liu, Feng ^b   Jiang, Jie Hong ^a   Zheng, Min Hua ^a   Kuno, Atsushi ^c,d   Narimatsu, Hisashi ^c,d   Zhang, Yan ^b,c,e   Zhang, Xin Xin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University   (China)

^c SCSB (China) AIST (Japan) Joint Medical Glycomics Laboratory   (China)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^e Collaborative Innovation Center of Systems Biomedicine ^*  (China)

Author keywords

chronic hepatitis B; liver fibrosis; Mac 2 binding protein; Wisteria floribunda agglutinin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ POSITIVE MAC 2 BINDING PROTEIN; BIOLOGICAL MARKER; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE TO ALANINE AMINOTRANSFERASE RATIO; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO; CHRONIC HEPATITIS B; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ELASTOGRAPH; ELASTOGRAPHY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STAGING; ADOLESCENT; AGED; BLOOD; CHINA; COMPLICATION; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; STATISTICAL MODEL; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; BIOMARKERS; CHINA; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LINEAR MODELS; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLANT LECTINS; RECEPTORS, N-ACETYLGLUCOSAMINE; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 85006746619     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13188     Document Type: Article

References (37)

1. Zheng X, Wang J, Yang D. Antiviral therapy for chronic hepatitis B in China. Med Microbiol Immunol 2015; 204: 115–20.
2. World Health Organization. Hepatitis B. (Updated July 2015). http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 15 September 2015).
3. Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med 2004; 350: 1118–29.
4. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol 2012; 56: 1171–80.
5. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165–73.
6. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614–8.
7. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835–47.
8. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 323–6.
9. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26.
10. Imperiale TF, Born LJ. Clinical utility of the AST/ALT ratio in chronic hepatitis C. Am J Gastroenterol 2001; 96: 919–20.
11. Cequera A, Garcia de Leon Mendez MC. Biomarkers for liver fibrosis: advances, advantages and disadvantages. Rev Gastroenterol Mex 2014; 79: 187–199.
12. Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065.
13. Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics 2015; 12: 683–93.
14. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009; 16: 418–29.
15. +-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50: 76–84.
16. Abe M, Miyake T, Kuno A, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50: 776–84.
17. Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol 2015; 110: 857–64.
18. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563–70.
19. Fujiyoshi M, Kuno A, Gotoh M, et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015; 50: 1134–44.
20. +-M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016; 36: 293–301.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289–93.
22. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–50.
23. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838–45.
24. Jia J, Hou J, Ding H, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2015; 30: 756–62.
25. Wong GL, Wong VW, Choi PC, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther 2011; 16: 165–72.
26. Ray Kim W, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 2016; 64: 773–80.
27. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastograph(Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36–44.
28. Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212–7.
29. European Association for the Study of the L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–85.
30. World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with chronic Hepatitis B infection. 2015. (accessed 15 September 2015).
31. Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006; 26: 666–72.
32. Jin W, Lin Z, Xin Y, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol 2012; 12: 14.
33. Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616–23.
34. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437–45.
35. Wu SD, Ni YJ, Liu LL, et al. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2012; 6: 360–8.
36. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380–4.
37. Hui CK, Lau E, Wu H, et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006; 35: 185–92.